These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 21255710)

  • 1. Germline mutations in cancer susceptibility genes: an overview for nurses.
    MacDonald DJ
    Semin Oncol Nurs; 2011 Feb; 27(1):21-33. PubMed ID: 21255710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modifying cancer risk factors: the gene-environment interaction.
    Giarelli E; Jacobs LA
    Semin Oncol Nurs; 2005 Nov; 21(4):271-7. PubMed ID: 16293515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Mutational analysis of breast/ovarian cancer hereditary predisposition gene BRCA1 in Tunisian women].
    Mestiri S; Monastiri K; Ben Ahmed S; Bouaouina N; Presneau N; Bignon YJ; Khairi H; Chouchane L
    Arch Inst Pasteur Tunis; 2000; 77(1-4):11-5. PubMed ID: 14658222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex differences in cancer risk among germline p53 mutation carriers.
    Chompret A; Brugières L; Bonaïti-Pellié C; Feunteun J
    Br J Cancer; 2004 Aug; 91(3):603-4. PubMed ID: 15280910
    [No Abstract]   [Full Text] [Related]  

  • 5. Genetic cancer risk assessment.
    Aiello-Laws L
    Semin Oncol Nurs; 2011 Feb; 27(1):13-20. PubMed ID: 21255709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers.
    Nichols KE; Malkin D; Garber JE; Fraumeni JF; Li FP
    Cancer Epidemiol Biomarkers Prev; 2001 Feb; 10(2):83-7. PubMed ID: 11219776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The biology of cancer: what do oncology nurses really need to know.
    Eggert J
    Semin Oncol Nurs; 2011 Feb; 27(1):3-12. PubMed ID: 21255708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions.
    Lancaster JM; Powell CB; Kauff ND; Cass I; Chen LM; Lu KH; Mutch DG; Berchuck A; Karlan BY; Herzog TJ;
    Gynecol Oncol; 2007 Nov; 107(2):159-62. PubMed ID: 17950381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scoping the family history: assessment of Lynch syndrome (hereditary nonpolyposis colorectal cancer) in primary care settings--a primer for nurse practitioners.
    Maradiegue A; Jasperson K; Edwards QT; Lowstuter K; Weitzel J
    J Am Acad Nurse Pract; 2008 Feb; 20(2):76-84. PubMed ID: 18271762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer risks in LKB1 germline mutation carriers.
    Mehenni H; Resta N; Park JG; Miyaki M; Guanti G; Costanza MC
    Gut; 2006 Jul; 55(7):984-90. PubMed ID: 16407375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Genetic factors involved in cancer susceptibility].
    Kohno T; Yokota J
    Gan To Kagaku Ryoho; 2002 Jul; 29(7):1255-62. PubMed ID: 12146010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low frequency of AXIN2 mutations and high frequency of MUTYH mutations in patients with multiple polyposis.
    Lejeune S; Guillemot F; Triboulet JP; Cattan S; Mouton C; ; Porchet N; Manouvrier S; Buisine MP
    Hum Mutat; 2006 Oct; 27(10):1064. PubMed ID: 16941501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators.
    Gayther SA; de Foy KA; Harrington P; Pharoah P; Dunsmuir WD; Edwards SM; Gillett C; Ardern-Jones A; Dearnaley DP; Easton DF; Ford D; Shearer RJ; Kirby RS; Dowe AL; Kelly J; Stratton MR; Ponder BA; Barnes D; Eeles RA
    Cancer Res; 2000 Aug; 60(16):4513-8. PubMed ID: 10969800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hereditary non polyposis colorectal cancer].
    Dieumegard B
    Ann Med Interne (Paris); 2001 Sep; 152(5):317-21. PubMed ID: 11593143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No germline FH mutations in familial breast cancer patients.
    Kiuru M; Lehtonen R; Eerola H; Aittomäki K; Blomqvist C; Nevanlinna H; Aaltonen LA; Launonen V
    Eur J Hum Genet; 2005 Apr; 13(4):506-9. PubMed ID: 15523491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Germline mutations in fumarate hydratase (FH) do not predispose to prostate cancer.
    Bevan S; Edwards SM; Ardern Jones A; Dowe A; Southgate C; Dearnaley D; Easton DF; Houlston RS; Eeles RA;
    Prostate Cancer Prostatic Dis; 2003; 6(1):12-4. PubMed ID: 12664059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germline ATBF1 mutations and prostate cancer risk.
    Xu J; Sauvageot J; Ewing CM; Sun J; Liu W; Isaacs SD; Wiley KE; Diaz L; Zheng SL; Walsh PC; Isaacs WB
    Prostate; 2006 Jul; 66(10):1082-5. PubMed ID: 16637072
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epimutations and cancer predisposition: importance and mechanisms.
    Hesson LB; Hitchins MP; Ward RL
    Curr Opin Genet Dev; 2010 Jun; 20(3):290-8. PubMed ID: 20359882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization and expression of the human WNT4; lack of associated germline mutations in high--to moderate--risk breast and ovarian cancer.
    Peltoketo H; Allinen M; Vuosku J; Kujala S; Lundan T; Salminen A; Winqvist R; Vainio S
    Cancer Lett; 2004 Sep; 213(1):83-90. PubMed ID: 15312687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular analysis of the BRCA1 and BRCA2 genes in 32 breast and/or ovarian cancer Spanish families.
    Osorio A; Barroso A; Martínez B; Cebrián A; San Román JM; Lobo F; Robledo M; Benítez J
    Br J Cancer; 2000 Apr; 82(7):1266-70. PubMed ID: 10755399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.